<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Gilead to Test Remdesivir Delivered Through Inhalation
Image Overlay - Gilead to Test Remdesivir Delivered Through Inhalation

Gilead to Test Remdesivir Delivered Through Inhalation

July 3, 2020

Gilead to Test Remdesivir Delivered Through Inhalation

Gilead will begin testing an inhaled version of their leading COVID-19 treatment, Remdesivir. It is currently administered to patients intravenously in a hospital setting, though delivery via a nebulizer is decidedly more patient-centric. Regardless of dosage form, Yourway has the means to transport, store, and ship even the most sensitive clinical trial samples globally.

 Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?